Hobby Gerren P, Karaduta Oleg, Dusio Giuseppina F, Singh Manisha, Zybailov Boris L, Arthur John M
Division of Nephrology, University of Arkansas for Medical Sciences , Little Rock, Arkansas.
Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences , Little Rock, Arkansas.
Am J Physiol Renal Physiol. 2019 Jun 1;316(6):F1211-F1217. doi: 10.1152/ajprenal.00298.2018. Epub 2019 Mar 13.
The gut microbiome is composed of a diverse population of bacteria that have beneficial and adverse effects on human health. The microbiome has recently gained attention and is increasingly noted to play a significant role in health and a number of disease states. Increasing urea concentration during chronic kidney disease (CKD) leads to alterations in the intestinal flora that can increase production of gut-derived toxins and alter the intestinal epithelial barrier. These changes can lead to an acceleration of the process of kidney injury. A number of strategies have been proposed to interrupt this pathway of injury in CKD. The purpose of this review is to summarize the role of the gut microbiome in CKD, tools used to study this microbial population, and attempts to alter its composition for therapeutic purposes.
肠道微生物群由多种细菌组成，这些细菌对人类健康既有有益影响，也有不利影响。微生物群最近受到了关注，并且越来越多地被认为在健康和多种疾病状态中发挥着重要作用。慢性肾脏病（CKD）期间尿素浓度升高会导致肠道菌群发生改变，从而增加肠道源性毒素的产生并改变肠道上皮屏障。这些变化会导致肾损伤进程加速。已经提出了多种策略来阻断CKD中的这一损伤途径。本综述的目的是总结肠道微生物群在CKD中的作用、用于研究这一微生物群体的工具，以及为治疗目的而改变其组成的尝试。
